RLAYRelay Therapeutics, Inc.

RLAY Stock Price, Valuation & Chart | Relay Therapeutics, Inc.

Compare

$18.510+0.02 (+0.11%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology RLAY intrinsic value RLAY calculated fair value vs price

Overview Financials Dividends Ratios

RLAY Historical price chart

RLAY Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization4.06B

PE Ratio-11.79

EPS-1.57

Trading Volume2.11M

Today's High/Low19.27/18.29

Dividend Yield0.00

52 Week High/Low21.27/3.58

Shares Outstanding219.14M

RLAY Financial Statement

RLAY Analyst ratings

RLAY Analysis & performance metrics

RLAY Company profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing…

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor…

RLAY Management team

Name

Position

Matthew P. Jacobson Ph.D.

Founder

Sanjiv K. Patel M.A., M.B.A., M.D., MBBSCEO

Chief Executive Officer, President & Director

Beni B. Wolf M.D., Ph.D.

Chief Medical Officer & Head of Precision Medicine

Donald A. Bergstrom M.D., Ph.D.

President of Research & Development

Peter Rahmer

Chief Corporate Development Officer

Dorothee Kern Ph.D.

Founder

Jim Watters Ph.D.

Chief Scientific Officer

David Elliot Shaw Ph.D.

Founder

Name

Position

Matthew P. Jacobson Ph.D.

Founder

Sanjiv K. Patel M.A., M.B.A., M.D., MBBSCEO

Chief Executive Officer, President & Director

Beni B. Wolf M.D., Ph.D.

Chief Medical Officer & Head of Precision Medicine

Donald A. Bergstrom M.D., Ph.D.

President of Research & Development

Peter Rahmer

Chief Corporate Development Officer

Dorothee Kern Ph.D.

Founder

Jim Watters Ph.D.

Chief Scientific Officer

David Elliot Shaw Ph.D.

Founder

Management Team

Matthew P. Jacobson Ph.D.

Founder

Sanjiv K. Patel M.A., M.B.A., M.D., MBBSCEO

Chief Executive Officer, President & Director

Beni B. Wolf M.D., Ph.D.

Chief Medical Officer & Head of Precision Medicine

Donald A. Bergstrom M.D., Ph.D.

President of Research & Development

Peter Rahmer

Chief Corporate Development Officer

Dorothee Kern Ph.D.

Founder

Jim Watters Ph.D.

Chief Scientific Officer

David Elliot Shaw Ph.D.

Founder

Management

Matthew P. Jacobson Ph.D.

Founder

Sanjiv K. Patel M.A., M.B.A., M.D., MBBSCEO

Chief Executive Officer, President & Director

Beni B. Wolf M.D., Ph.D.

Chief Medical Officer & Head of Precision Medicine

Donald A. Bergstrom M.D., Ph.D.

President of Research & Development

Peter Rahmer

Chief Corporate Development Officer

Dorothee Kern Ph.D.

Founder

Jim Watters Ph.D.

Chief Scientific Officer

David Elliot Shaw Ph.D.

Founder

Total 8 executives

RLAY Frequently asked questions

What is Relay Therapeutics, Inc. (RLAY) Stock Price?

Current stock price of Relay Therapeutics, Inc. (RLAY) stock is $18.510. The stock price is +0.11% higher in the session. The intraday range can be seen from this page. Volume of Relay Therapeutics, Inc. (RLAY) stock is 2.11M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Relay Therapeutics, Inc. (RLAY) stock price going up or down today?

The stock price of Relay Therapeutics, Inc. (RLAY) can change with earnings, company news, and overall market sentiment. Relay Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Relay Therapeutics, Inc. stock expensive at its current price?

Whether Relay Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for RLAY on this page is -11.79. EPS on this page is -1.57. Compare those figures with peers and growth expectations before deciding if the current Relay Therapeutics, Inc. price is justified.

How has the stock price of Relay Therapeutics, Inc. (RLAY) performed historically?

Historical performance for Relay Therapeutics, Inc. (RLAY) is shown on the price chart on this page. Review multi-period moves alongside volume to see how RLAY reacted to past earnings and market events.

Should I buy Relay Therapeutics, Inc. (RLAY) stock, at this price?

Buying Relay Therapeutics, Inc. (RLAY) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.